Spark Therapeutics Inc (NASDAQ:ONCE) – Investment analysts at Leerink Swann issued their Q1 2018 EPS estimates for shares of Spark Therapeutics in a report issued on Monday. Leerink Swann analyst J. Schwartz anticipates that the biotechnology company will earn ($1.75) per share for the quarter. Leerink Swann currently has a “Market Perform” rating and a $49.00 target price on the stock. Leerink Swann also issued estimates for Spark Therapeutics’ FY2019 earnings at ($2.90) EPS and FY2020 earnings at ($2.57) EPS.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same quarter in the previous year, the business posted ($1.07) EPS. The company’s revenue for the quarter was up 45.8% on a year-over-year basis.

A number of other brokerages have also weighed in on ONCE. Goldman Sachs Group restated a “buy” rating and set a $111.00 price objective on shares of Spark Therapeutics in a research report on Friday, October 6th. BMO Capital Markets set a $89.00 price objective on Spark Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 10th. Cowen restated a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Chardan Capital restated a “buy” rating and set a $100.00 price objective on shares of Spark Therapeutics in a research report on Friday, October 13th. Finally, Raymond James Financial began coverage on Spark Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $96.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $76.19.

Shares of Spark Therapeutics (ONCE) traded up $1.15 on Thursday, hitting $45.91. The stock had a trading volume of 1,895,700 shares, compared to its average volume of 481,123. Spark Therapeutics has a one year low of $41.06 and a one year high of $91.75.

In other news, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total value of $356,600.00. Following the transaction, the insider now directly owns 215,000 shares of the company’s stock, valued at approximately $15,333,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $70.14, for a total value of $701,400.00. Following the completion of the transaction, the chief financial officer now directly owns 12,500 shares in the company, valued at $876,750. The disclosure for this sale can be found here. Insiders sold a total of 1,068,809 shares of company stock worth $89,809,385 in the last quarter. Corporate insiders own 7.30% of the company’s stock.

A number of hedge funds have recently bought and sold shares of ONCE. Teachers Advisors LLC raised its stake in Spark Therapeutics by 1.9% during the 1st quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after buying an additional 650 shares during the period. Russell Investments Group Ltd. raised its stake in Spark Therapeutics by 81.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock worth $1,507,000 after buying an additional 11,335 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Spark Therapeutics by 8.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 94,920 shares of the biotechnology company’s stock worth $5,671,000 after buying an additional 7,169 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in Spark Therapeutics during the 2nd quarter worth approximately $829,000. Finally, Rhumbline Advisers raised its stake in Spark Therapeutics by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 26,278 shares of the biotechnology company’s stock worth $1,570,000 after buying an additional 3,626 shares during the period. 94.94% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/14/spark-therapeutics-inc-forecasted-to-earn-q1-2018-earnings-of-1-75-per-share-once.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.